METHYL ETHYL KETONE

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
72.0 1.0 0 1 17.0 1 0.75
CAS
78933
UNII
6PT9KLV9IO
SYNONYMS
ZINC ID(s)
Availability
Present in 44 ZINC catalogs

Known Active Genes

There has not been any activity reported at 10μM or less for this excipient (per ChEBML)

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT02225574 2015-03-01 An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T) Phase 1/Phase 2 Recruiting
NCT02049801 2014-12-01 MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1 Recruiting
NCT02089230 2014-08-01 Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy Phase 1/Phase 2 Recruiting
NCT02105350 2014-06-01 A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer Phase 1 Not Yet Recruiting
NCT02041481 2014-06-01 MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer Phase 1 Recruiting
NCT01849874 2013-06-01 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Phase 3 Recruiting
NCT01726738 2012-10-01 LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations Phase 2 Recruiting
NCT01649336 2012-07-01 A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Phase 1 Active, Not Recruiting
NCT01378377 2011-06-01 Combination Trial MSC1936369B With Temsirolimus Phase 1 Completed
NCT01204177 2010-12-01 Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer. Phase 2 Completed
NCT01085331 2010-03-01 MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) Phase 1/Phase 2 Completed
NCT01016483 2009-11-01 Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer Phase 1/Phase 2 Active, Not Recruiting
NCT00959127 2009-08-01 A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer Phase 1 Completed
NCT00828165 2009-01-01 A Safety Study of ARRY-300 in Healthy Subjects Phase 1 Completed
NCT00650767 2008-03-01 A Study of ARRY-438162 in Patients With Rheumatoid Arthritis Phase 2 Completed
NCT00085787 2004-06-01 A Study of ARRY-142886 in Patients With Advanced Cancer Phase 1 Completed

(Browse) Purchasable Analogs in ZINC

Dosages

Route Formulation Per Unit Dose
Oral Tablet
Oral Tablet, Delayed Action, Enteric Coated 61MG

More Information

Usage Over Time

Comments